CD34 Expression as a marker of progression of chronic hepatitis C

Agamy, Maha Mohamed; Galal, Ghada Moustafa; Salah ElDeen, Eman Muhammad; Ahmad, Nagwa Sayed; Mohammad, Asmaa Naser; Mahmoud, Sheren Farrag

doi:10.21608/smj.2017.34044

CD34 Expression as a marker of progression of chronic hepatitis C

Document Type : Original Article

Authors

¹ Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, Sohag University.

² Department of pathology, Faculty of Medicine, Sohag University.

³ Department of Medical Biochemistry, Faculty of Medicine, Sohag University.

10.21608/smj.2017.34044

Abstract

Background
In Egypt, the rate of death/transplantation, decompensation and HCC in patients with compensated HCV cirrhosis is 4.58%, 6.37% and 3.36%, respectively. It is estimated that Egyptian patients with HCV cirrhosis had an annual incidence of HCC with 5.3%. CD34 is a 110-kDa transmembrane glycoprotein present on leukemic cells, endothelial cells and stem cells). CD34 is preferentially expressed on the surface of regenerating or migrating endothelial cells and is a marker of proliferating endothelial cells in the growing sprouts during angiogenesis.
Aim of the work: The aim of the present study was to analyses the correlation between CD34 and the clinical severityof CHC.
Methods: A total of 70 adult patients with chronic hepatitis C infection in various stages with no evidence of cirrhosis, were recruited for the study. We studied the expression of CD34 in liver specimens from chronic HCV infected patients using a computer-based analysis of immunohistochemical staining and confirmed it by Western Blot.
Results: CD34 significantly related with AST and ALT levels. Also, it is significantly related with alpha-fetoprotein and prothrombin concentration. Also, There was a significant relation between CD34 and fibrosis stage.
Conclusion: A direct correlation existed between endothelial cell markers CD34 expression and the progression of fibrosis in chronic hepatitis C. The immunohistochemical methods of this molecule can be important clue in future prognostic strategies.

References

1- Blach S, Zeuzem S, Manns M, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.Lancet GastroenterolHepatol. 2016;2(3):161–176.

2- Alazawi W, Cunningham M, Dearden J, Foster GR. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment PharmacolTher. 2010;32(3):344–355.

3- Eltabbakh M, Zaghla H, Abdel-Razek W, et al. Utility and cost effectiveness of screening for hepatocellular carcinoma in a resource limited setting. Med Oncol. 2015;32(4):432–437.

4- L.C. Strauss, S.D. Rowley, V.F. LaRussa, S.J. Sharkis, R.K. Stuart, C.I. Civin, et al., Antigenic analysis of hematopoiesis. Characterization of My-10 antigen expression by normal lymphohematopoietic progenitor cells, Exp. Hematol. 14 (9) (1986) 878–886.

5- F. Tanaka, Y. Otake, K. Yanagihara, Y. Kawano, R. Miyahara, M. Li, et al., Evaluation of angiogenesis in non-small cell lung cancer. Comparison between anti-CD34 and anti-CD105 antibody, Clin. Cancer Res. 7 (2001) 3410–3415.

6- M. Fernandez, D. Semela, J. Bruix J, I. Colle, M. Pinzani, J. Bosch, Angiogenesis in liver disease, J. Hepatol. 50 (2009) 604–620.

7- Chaparro M, Sanz-Cameno P, Trapero-Marugan M, Garcia-BueyL, Moreno-Otero R. Mechanisms of angiogenesis in chronicinflammatory liver disease. Ann Hepatol2007; 6:208–213.

8- Gabriel A, Kukla M, Wilk M, et al. Angiogenesis in chronichepatitis C is associated with inflammatory activity grade andfibrosis stage. Pathol Res Pract 2009; 205:758–764.

9- Mazzanti R, Messerini L, Monsacchi L, et al. CVH inducedby hepatitis C but not hepatitis B virus infection correlateswith increased liver angiogenesis. Hepatology 1997;25:229–234.

10. Messerini L, Novelli L, Comin CE. Microvessel density andclinicopathological characteristics in hepatitis C virus and hepatitisB virus related hepatocellular carcinoma. J ClinPathol2004;57:867–871.

11. Ohmori S, Shiraki K, Sugimoto K, et al. High expression ofCD34-positive sinusoidal endothelial cells is risk factor forhepatocellular carcinoma in patients with HCV-associatedchronic liver diseases. Hum Pathol2001; 32:1363–1370.

12- Pinzani M, Rombouts K, Colagrande S. Fibrosis in chronic liver diseases: diagnosis and management. J Hepatol 2005; 42(Suppl): S22–36.

13- Gabriel A, Kukla M, Wilk M, et al. Angiogenesis in chronichepatitis C is associated with inflammatory activity grade andfibrosis stage. Pathol Res Pract 2009; 205:758–764.

14. Kukla M, Gabriel A, Sabat D, et al. Association between liversteatosis and angiogenesis in chronic hepatitis C. Pol J Pathol2010;3:154–160.

15- Jain RK. Molecular regulation of vessel maturation. Nat Med2003; 9:685–693.

16- Lai WK, Adams DH. Angiogenesis and chronic inflammation;the potential for novel therapeutic approaches in chronic liverdisease. J Hepatol2005;45:7–11.

17- Girard JP, Springer TA. High endothelial venules (HEVs): specialized

endothelium for lymphocyte migration. Immunol Today1995;16:449–457.

18- Salcedo X, Medina J, Sanz-Cameno P, et al. The potential ofangiogenesis soluble markers in chronic hepatitis C. Hepatology2005;42:696–701.

19- Salcedo X, Medina J, Sanz-Cameno P. Review article: angiogenesismsoluble factors as liver disease markers. Aliment PharmacolmTher2005;22:23–30.